Explore a 34-minute webinar presented by Dr. Xiangjun Kong, Principal Scientist at Neogene Therapeutics, on the development of a T cell engineering platform for individualized neoantigen-specific TCR therapy. Gain insights into a promising new immunotherapy approach involving adoptive transfer of T cell receptor (TCR)-edited T cells targeting cancer neoantigens. Learn about the high-throughput, patient-specific platform developed to identify neoantigen-reactive TCRs. Discover Dr. Kong's extensive research background in functional screening, genome editing technologies, and novel targeted and immune therapy strategies for cancer. Understand the potential impact of this innovative approach on personalized cancer treatment.
Development of a T Cell Engineering Platform for Fully Individualized Neoantigen-Specific TCR Therapy
Overview
Syllabus
Development of a T cell engineering platform for fully individualized neoantigen specific TCR...
Taught by
Labroots
Related Courses
-
Identification of Tumor-Reactive T Cell Receptors Through Functional Single Cell Interaction Analysis for Personalized T Cell Therapy
-
A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer
-
Discovery of a Novel C0702 Restricted Epitope on MAGE A1 and Preclinical Development of an Enhanced TCR-T Cell Therapy
-
Immunotherapy for Gynecological Cancers
-
Engineering Enhanced Chimeric Antigen Receptor T-Cell Therapy
-
TCR Repertoire Profiling to Predict NSCLC Response to Immunotherapy - Feasibility Study
